Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

Abstract

ABSTRACT

Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept

“…Applying the MA-ETN63C8/MA-ETN61C1-HRP ELISA, mean ETN concentration in the 21 AS patient samples was 3.8 mg/ml (SD 2.2 mg/ml) at 24 wk of treatment. This finding is more or less in line with previous studies in AS (4,(18)(19)(20), in which mean ETN concentrations of ∼3 mg/ml were reported at 24 wk of therapy. In these studies, ETN was also captured through its ability to bind TNF; however, the set-up differed slightly from the TNF-coated ELISA described in this article, because a specific mouse mAb was used to immobilize TNF on the plate.…”

“…However, anti-ETN Abs were not detected in any of the patient sera tested, which seems to support the hypothesis that ETN is not or only marginally immunogenic (18). Although there is a possibility that some positive results were missed as a result of interference of drug in the sample, the overall reported frequency of anti-ETN Abs is low (19).…”

Immunogenicity, the elephant in the room. Comment on “Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases”

“…The authors confirm at least 10 years of observations that immunogenicity most notably with monoclonal antibody therapies results in treatment failure [1]. By contrast, receptor-based constructs seem less likely to be associated with the development of patient-derived antibody failure [2][3][4]. Also as pointed out by the authors, the development of neutralizing antibodies is independent of underlying immune disease.…”

Clinical Experience With Etanercept in the Treatment of Patients With Ankylosing Spondylitis

“…de Vries и со-авт. [24] показали, что концентрация ЭТЦ в сыворотке не взаимосвязана с клиническим ответом. У некоторых па-циентов, получавших ЭТЦ, в сыворотке были обнаруже-ны антитела к препарату.…”